Announced at the annual meeting of the American Association for Cancer Research, SU2C's scientific partner, the Pancreatic Cancer Collective will work to accelerate research for pancreatic cancer patients who desperately need better treatments. With an initial commitment of $25 million from Lustgarten and SU2C, the collective will work to inspire new collaborations, leverage artificial intelligence approaches to the disease, improve and develop new diagnoses and treatments, and support the next generation of pancreatic cancer investigators. The partnership also will seek to engage thought leaders, researchers, institutions, and pharmaceutical companies to innovate and accelerate research on the disease.
To that end, the first request for applications will seek projects focused on increasing the number of innovative and effective therapies for pancreatic cancer treatments, with the collective inviting applications from teams currently supported by SU2C and the Lustgarten Foundation as well as researchers and institutions new to the organizations.
"This is a watershed moment in the field of pancreatic cancer research," said Nobel Laureate Phillip A. Sharp, PhD, chair of the SU2C scientific advisory committee and institute professor at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. "Through the collective, these two organizations are uniquely positioned to engage and influence medical institutions, researchers, and companies to achieve meaningful results faster."